RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.

Add to Collection
2021 Dec RCTs Fist_Author_Year_PM

Full Author : ['Berenbaum, Francis', 'Schnitzer, Thomas', 'Kivitz, Alan', 'Viktrup, Lars', 'Johnston, Elizabeth', 'Yang, Ruoyong', 'Whalen, Ed', 'Tive, Leslie', 'Semel, David']
Journal Title : International journal of clinical practice
Chapter : Section3
Journal Year : 2021
Cited by : Not Available

AIM: To assess the impact of pre-specified patient characteristics on efficacy and safety of subcutaneous tanezumab in patients with osteoarthritis (OA). METHODS: Data were pooled from two (efficacy; N = 1545) or three (safety; N = 1754) phase 3 placebo-c.....

Keywords : ["gender age disease severity body mass index", "subgroup analysis", "subcutaneous tanezumab", "placebocontrolle trial", "diabetes may", "affect response", "week", "treatment", "patient", "osteoarthritis"]